# Antimicrobial Resistance * **Definition:** The ability of microorganisms, such as bacteria, viruses, fungi, and parasites, to resist the effects of medications that once effectively treated them, leading to treatment failures and increased risk of disease spread, severe illness, and death. * **Taxonomy:** Healthcare Topics / Antimicrobial Resistance ## News * Selected news on the topic of **Antimicrobial Resistance**, for healthcare technology leaders * 3.2K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/20/2025 | [**Ambulatory Surgical & Emergency Center Services Market 2025: AI, Electrification, and ...**](https://www.linkedin.com/pulse/ambulatory-surgical-emergency-center-fotve/) | [[Linkedin]] | | 5/16/2025 | [**How Payer-Provider Collaboration is Creating A More Patient-Friendly Healthcare Industry**](https://hitconsultant.net/2025/05/16/how-payer-provider-collaboration-is-creating-a-more-patient-friendly-healthcare-industry/) | [[HIT Consultant]] | | 5/12/2025 | [**With CDC advisory panel disbanded, doctors fear impact: 'Long live hospital infections'**](https://www.chiefhealthcareexecutive.com/view/with-cdc-advisory-panel-disbanded-doctors-fear-impact-long-live-hospital-infections-) | [[Chief Healthcare Executive]] | | 4/11/2025 | [**News on antimicrobial resistance**](https://medicalxpress.com/tags/antimicrobial+resistance/) | [[MedicalXpress]] | | 3/24/2025 | [**Genomic sequencing reveals previously unknown genes that make microbes resistant to drugs and hard to kill**](https://www.chron.com/news/article/genomic-sequencing-reveals-previously-unknown-20237628.php) | [[Chron]] | | 3/24/2025 | [**Genomic sequencing reveals previously unknown genes that make microbes resistant to drugs and hard to kill**](https://phys.org/news/2025-03-genomic-sequencing-reveals-previously-unknown.html) | [[Phys Org]] | | 2/26/2025 | [**Antimicrobial Resistance Surveillance Market is expected to generate a revenue of USD ...**](https://www.prnewswire.com/news-releases/antimicrobial-resistance-surveillance-market-is-expected-to-generate-a-revenue-of-usd-9-86-billion-by-2032--globally-at-5-65-cagr-verified-market-research-302386177.html) | [[PR Newswire]] | | 2/18/2025 | [**Microbiology Culture Market Set to Surge to $13.6 Billion by 2031, Driven by ... - Yahoo Finance**](https://finance.yahoo.com/news/microbiology-culture-market-set-surge-141200052.html) | [[Yahoo Finance]] | | 1/28/2025 | [**Socioeconomic Inequities Have a Significant Impact on Treatment of Antimicrobial Resistant Infections**](https://www.pharmacytimes.com/view/socioeconomic-inequities-have-a-significant-impact-on-treatment-of-antimicrobial-resistant-infections) | [[Pharmacy Times]] | | 1/23/2025 | [**'Every blast is an open wound': How the chaos of war breeds deadly superbugs that spread around the world**](https://medicalxpress.com/news/2025-01-blast-wound-chaos-war-deadly.html) | [[MedicalXpress]] | | 1/23/2025 | [**'Every blast is an open wound': How the chaos of war breeds deadly superbugs that spread around ...**](https://medicalxpress.com/news/2025-01-blast-wound-chaos-war-deadly.html?deviceType=desktop) | [[MedicalXpress]] | | 1/14/2025 | [**Anticoagulant Reversal Drugs Market to Grow by USD 1.27 Billion from 2025-2029, Driven by Rising Coagulation Disorders and AI-Redefined Market Landscape - Technavio**](https://www.prnewswire.com/news-releases/anticoagulant-reversal-drugs-market-to-grow-by-usd-1-27-billion-from-2025-2029--driven-by-rising-coagulation-disorders-and-ai-redefined-market-landscape---technavio-302349090.html) | [[PR Newswire]] | | 12/31/2024 | [**Antimicrobial Resistance Diagnostic Markets, Strategies and Trends Report 2024 with ...**](https://finance.yahoo.com/news/antimicrobial-resistance-diagnostic-markets-strategies-105800735.html) | [[Yahoo Finance]] | | 12/18/2024 | [**Sustainable antimicrobial resistance surveillance: time for a global funding mechanism**](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00649-2/abstract) | [[The Lancet]] | | 12/12/2024 | [**The lab effect: How an efficient and effective lab strengthens your hospital's success**](https://www.beckershospitalreview.com/patient-safety-outcomes/the-lab-effect-how-an-efficient-and-effective-lab-strengthens-your-hospitals-success.html) | [[Beckers Hospital Review]] | | 12/3/2024 | [**Pharmacists Play a Critical Role in Preventing Antimicrobial Resistance**](https://www.pharmacytimes.com/view/pharmacists-play-a-critical-role-in-preventing-antimicrobial-resistance) | [[Pharmacy Times]] | | 11/14/2024 | [**Advancing the management of maternal, fetal, and neonatal infection through harnessing ...**](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00217-6/fulltext?rss=yes) | [[The Lancet]] | | 11/13/2024 | [**Using digital health to address antimicrobial resistance**](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00251-6/fulltext) | [[The Lancet]] | | 11/6/2024 | [**Sewage surveillance for combating antimicrobial resistance proves more powerful than individual testing**](https://medicalxpress.com/news/2024-11-sewage-surveillance-combating-antimicrobial-resistance.html) | [[MedicalXpress]] | | 11/6/2024 | [**Sewage surveillance for combating antimicrobial resistance proves more powerful than ...**](https://medicalxpress.com/news/2024-11-sewage-surveillance-combating-antimicrobial-resistance.html?deviceType=desktop) | [[MedicalXpress]] | | 11/1/2024 | [**AI tackles huge problem of antimicrobial resistance in intensive care**](https://medicalxpress.com/news/2024-11-ai-tackles-huge-problem-antimicrobial.html) | [[MedicalXpress]] | | 11/1/2024 | [**AI provides same-day assessments of antimicrobial resistance in ICUs**](https://www.news-medical.net/news/20241101/AI-provides-same-day-assessments-of-antimicrobial-resistance-in-ICUs.aspx) | [[News Medical Net]] | | 9/23/2024 | [**Tackling antimicrobial resistance with non-antibiotic therapeutic approaches and AI**](https://medicalxpress.com/news/2024-09-tackling-antimicrobial-resistance-antibiotic-therapeutic.html) | [[MedicalXpress]] | | 8/6/2024 | [**Pfizer to create 500 new jobs as it upgrades Australia manufacturing plant to help fight antimicrobial resistance**](https://www.fiercepharma.com/pharma/pfizer-create-500-new-jobs-it-upgrades-australia-manufacturing-plant-combat-antimicrobial) | [[FiercePharma]] | | 6/14/2024 | [**Infection Surveillance Solutions Market to Reach $1,100 Million by 2027, Driven by Robust 13.8% CAGR**](http://prsync.com/marketsandmarkets---hc/infection-surveillance-solutions-market-to-reach--million-by--driven-by-robust--cagr-4174560/) | [[PRSync]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **AMR Accelerator**: A public-private partnership aimed at addressing antimicrobial resistance through coordinated political action and funding. - **Wayne State University CEID**: Participates in World AMR Awareness Week to address the threat of antimicrobial resistance. - **bioMérieux**: A company providing innovative diagnostic solutions to enhance antibiotic use and combat antimicrobial resistance. - **Disperazol Pharma**: A biotechnology firm focused on developing compounds to dismantle biofilms of Gram-negative pathogens, committed to combating antimicrobial resistance (AMR). - **University of Zurich**: Utilizing AI to analyze antibiotic resistance in bacteria. - **Stanford University**: Conducted research indicating that short-term use of ciprofloxacin can lead to long-lasting antibiotic resistance in gut bacteria. - **Cytophenix**: A company focused on developing new diagnostic tests for antimicrobial resistance. - **Translational Research Institute (Brisbane)**: Researchers exploring antimicrobial peptides from horseshoe crabs and tarantulas to combat drug resistance in advanced melanoma. - **AUROBAC THERAPEUTICS**: A biopharmaceutical company focused on developing innovative treatments for bacterial infections and antimicrobial resistance. - **T2 Biosystems**: A company planning to launch direct-from-blood diagnostic tests targeting antimicrobial resistance and related infections. - **World Health Organization (WHO)**: An international public health agency leading global efforts to combat antimicrobial resistance through action plans and guidelines. - **Ondine Biomedical**: A life sciences company developing light-activated antimicrobials to combat infections without promoting resistance. - **Meitheal Pharmaceuticals**: A biopharmaceutical company that acquired XENLETA, a novel antibiotic, to address antimicrobial resistance. - **Glox Therapeutics**: A company focused on precision antibiotic therapies targeting antimicrobial resistance, led by experienced professionals in the field. - **WHO**: World Health Organization, responsible for global health initiatives and guidelines, including the prioritization of vaccine development against antimicrobial-resistant pathogens. - **ArrePath, Inc.**: A biotechnology firm focused on developing new anti-infectives using AI and machine learning to combat multidrug-resistant infections. - **Immuron Limited**: A company specializing in developing therapeutic drug candidates to combat antimicrobial resistant pathogens using a proprietary technology platform. - **Resistomap Oy**: Developing SmartChip technology for high-throughput gene quantification of AMR-related genes. - **Singapore General Hospital**: Developing AI solutions to optimize antibiotic prescriptions. - **iFAST Diagnostics**: A UK diagnostics company advancing rapid antibiotic susceptibility testing technology. ### Partnerships and Collaborations - **AMR Accelerator**: Involves numerous European projects and organizations to combat antimicrobial resistance. - **Cystic Fibrosis Antimicrobial Resistance Syndicate**: A collaborative initiative to develop novel antibiotics for cystic fibrosis patients, involving Glox Therapeutics. - **WHO and Vaccine Developers**: Collaboration to prioritize vaccine research for endemic pathogens with rising antimicrobial resistance. - **Virginia Tech**: Utilizing sewage surveillance to monitor antimicrobial resistance in waterborne diseases. - **ArrePath and PACE**: Collaboration to support antibiotic development efforts against multidrug-resistant infections. - **Immuron Limited and Monash University**: A research collaboration aimed at developing therapeutic candidates against antimicrobial resistant pathogens. - **AUROBAC THERAPEUTICS and GENERARE Bioscience**: Collaboration to enhance research capabilities in developing precision antimicrobials. - **Cystic Fibrosis Foundation and NIH**: Researching innovative treatments for resistant infections, including bacteriophage therapy. - **Eli Lilly and OpenAI**: A partnership to leverage generative AI for the discovery of new antimicrobial treatments. - **Disperazol Pharma and AMR Industry Alliance**: Disperazol Pharma joined the AMR Industry Alliance to support early-stage companies in developing innovative antimicrobial solutions. - **TARGET Initiative**: A collaboration involving Phare Bio, MIT, and Harvard's Wyss Institute to accelerate antibiotic discovery using generative AI. - **AMR-Policy GPT Tool Development**: An international research team created this AI tool to assist in developing National Action Plans for AMR. - **T2 Biosystems and CDC**: Collaboration to develop a diagnostic test for Candida auris. - **Biotia and Medical Institutions**: Partnerships aimed at integrating BIOTIA-ID into clinical workflows to improve UTI diagnostics. - **Yale's Center for Phage Biology and Therapy**: Collaborating with health organizations to establish a coordinated system for phage therapy in the U.S. - **African Medical Devices Forum (AMDF)**: An initiative aimed at improving regulatory harmonization and collaboration for better access to diagnostic tools in Africa. - **Healthcare Infection Control Practices Advisory Committee**: Four prominent infectious disease organizations urged the CDC to reinstate this committee, emphasizing its critical role in infection prevention and healthcare safety. - **Meiji Seika Pharma and MPM BioImpact**: Investment agreement to enhance biotechnology strategies and address unmet medical needs in infectious diseases. - **TRIC-TB Program**: Funded by the European Union, this program collaborates with GSK to develop a tuberculosis candidate, alpibectir. ### Innovations, Trends, and Initiatives - **AMR Lens Report**: Highlights the escalating crisis of antimicrobial resistance, calling for immediate coordinated action across sectors to mitigate its impact on global health. - **Antimicrobial Stewardship Programs**: Initiatives to promote responsible antibiotic use and combat resistance, highlighted during Antibiotic Awareness Week. - **T2Resistance Panel**: A forthcoming diagnostic tool aimed at identifying antimicrobial resistance directly from blood samples. - **Sewage Surveillance**: Research indicates that monitoring sewage for antimicrobial resistance is more effective than individual testing. - **AMR-Policy GPT**: An AI chatbot assisting governments in developing effective policies to combat antimicrobial resistance. - **AMR Accelerator**: A program calling for investment in new antibiotics and antimicrobial resistance research to ensure sustainable public health efforts. - **Antimicrobial Peptides**: Research into peptides derived from horseshoe crabs and tarantulas shows promise in overcoming drug resistance, particularly in advanced melanoma. - **Precision Antibiotics**: Research into targeting unique metabolic pathways in pathogens to develop tailored antimicrobial therapies. - **T6SS Technology**: Research on friendly bacteria using Type 6 Secretion Systems to combat AMR by injecting toxins into rival microbes. - **AI in AMR Research**: Recent studies indicate that AI and non-antibiotic therapeutic approaches may effectively address AMR. - **Digital Health Technologies (DHTs)**: Tools that enhance the diagnosis, treatment, and monitoring of bacterial infections while preventing AMR, with a projected market growth rate of 18.6%. - **AI in Diagnostics**: Artificial intelligence is being utilized for same-day assessments of antimicrobial resistance, significantly reducing diagnosis time from days to hours. - **Digital Health Tools**: Technologies enhancing early diagnosis of bacterial infections, crucial for understanding local AMR patterns. - **EUCAST-GPT-expert**: An AI system developed by the University of Zurich to analyze antibiotic resistance in bacteria. - **Phage Therapy**: An emerging treatment option using bacteriophages to target antibiotic-resistant infections, though its use is limited by regulatory challenges. - **Short-Course Antibiotic Treatments**: Research indicates that tailored short-course antibiotics are effective in treating conditions like ventilator-associated pneumonia, helping to mitigate AMR. - **AMR Action Fund**: Eli Lilly has allocated $100 million to this fund to provide access to new antibiotics by 2030. - **Light-Activated Antimicrobials**: Ondine Biomedical's Steriwave technology aims to reduce surgical site infections and antibiotic usage. - **Rapid Antibiotic Susceptibility Testing**: iFAST's technology can determine effective antibiotics in under three hours, significantly reducing wait times. ### Challenges and Concerns - **Antimicrobial Resistance Crisis**: The World Health Organization identifies AMR as a significant global health threat, with projected deaths reaching 10 million by 2050. - **Rising AMR Rates**: A comprehensive study in China revealed a concerning rise in antimicrobial resistance among diarrheagenic E. coli, indicating a growing threat to food safety and public health. - **Overprescription of Antibiotics**: Leading to a significant global threat of antimicrobial resistance, complicating treatment of infections. - **Healthcare Infrastructure in Conflict Zones**: Destruction of healthcare facilities and disrupted vaccination programs exacerbate antimicrobial resistance. - **Antibiotic Overuse**: Increased antibiotic usage during the COVID-19 pandemic has contributed to the rise of antibiotic-resistant superbugs. - **Funding Shortages**: Insufficient investment in antimicrobial research and development, impacting the effectiveness of new treatments. - **Environmental Resistance**: Colistin-resistant bacteria found in Nigeria raise concerns about environmental exposure contributing to resistance. - **Low Profitability of Antibiotic Development**: The economic challenges in developing new antibiotics hinder efforts to combat AMR. - **Education Gaps**: A global investigation highlights the need for improved antimicrobial education among healthcare students to combat AMR effectively. - **Socioeconomic Factors**: Limited access to healthcare in lower-income neighborhoods increases the risk of infectious diseases and antimicrobial resistance. - **Global Health Threat**: The WHO predicts drug-resistant diseases could lead to up to 10 million deaths annually by 2050, highlighting the urgency of addressing AMR. - **Healthcare Disparities**: Low- and middle-income countries face significant challenges in combating AMR due to disparities in healthcare access and resources. - **Global AMR Surveillance Gaps**: Significant deficiencies in laboratory capacity for effective AMR detection, particularly in low- and middle-income countries. - **Drug Commercialization**: High costs and lower profitability deter large pharmaceutical companies from investing in antibiotic development. - **Funding Cuts**: The cancellation of over $11 billion in public health funding is expected to significantly impact infectious disease research and public health programs, hindering efforts to combat AMR. - **Regulatory Barriers**: Strict FDA regulations hinder the broader use of promising treatments like phage therapy. ## Related Topics [[Antibiotic Resistance]]